Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GRAILGRAL -3.72%12 Debt-to-Equity is 0.02 as of Mar. 2026, which is at its 10-year median of 0.02. GuruFocus rates GRAL with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 182 Medical Diagnostics & Research companies, GRAIL ranks better than 91.76% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for GRAIL's Debt-to-Equity or its related term are showing as below:
GRAL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.02 Max: 0.03
Current: 0.02
During the past 6 years, the highest Debt-to-Equity Ratio of GRAIL was 0.03. The lowest was -0.03. And the median was 0.02.
GRAL's Debt-to-Equity is ranked better than 91.76% of 182
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.325
vs GRAL: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
GRAIL Debt-to-Equity Related Terms
GRAIL Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for GRAIL's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, GRAIL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRAIL Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where GRAIL's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRAIL (GRAL) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on GRAIL and its competitors. This is near median its historical median of 0.02. According to the industry distribution chart, GRAIL ranks #15 out of 182 companies in the Medical Diagnostics & Research industry, placing it in the top 8.2%.
Is GRAIL's Debt-to-Equity too high?
GRAIL's current Debt-to-Equity of 0.02 is near median its 10-year median of 0.02. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. GRAIL's value of 0.02 is 93.8% below this industry median. Based on the distribution chart, GRAIL ranks #15 out of 182 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, GRAIL has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's Debt-to-Equity compare to ADPT and WGS?
According to the Medical Diagnostics & Research industry distribution chart, GRAIL ranks #15 out of 182 companies for Debt-to-Equity. This places GRAIL in the top 8% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.33. GRAIL's value of 0.02 is 93.8% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.33, GRAIL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 182 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GRAIL's current Debt-to-Equity of 0.02 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on GRAIL and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRAIL's current Debt-to-Equity is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (GRAL) has a current Debt-to-Equity of 0.02. The current Debt-to-Equity is 0.02, which is near median its 10-year median of 0.02 and 93.8% below the Medical Diagnostics & Research industry median of 0.33. GRAIL's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For GRAIL (GRAL), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
12GF Score
Get the complete analysis for GRAL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRAL has been successfully added to your 
